The intermediate filament protein vimentin is a potential target antigen for autoantibodies in some infectious and autoimmune diseases. Because endothelial cells contain an extensive interconnecting cytoplasmic network of vimentin, we examined the relationship between anti-vimentin and antiendothelial cell antibodies (AECAs). We measured the level of anti-vimentin antibodies in patients with systemic autoimmune diseases (n=42), healthy blood donors (n=58), and patients with acute inflammation and showing anti-vimentin immunofluorescence (n=50). AECAs were detected by indirect immunofluorescence in human umbilical vein endothelial cells. Anti-vimentin antibodies were detected by indirect immunofluorescence in HEp-2 cells, and levels of anti-vimentin antibodies were measured using an enzyme-linked immunosorbent assay. We did not find significant differences in anti-vimentin levels between AECA-positive and -negative samples for any of the groups; however, serum anti-vimentin antibody levels were significantly higher in patients with acute non-autoimmune inflammatory diseases than in patients with systemic autoimmune diseases or healthy controls. There were no differences between the levels of anti-vimentin antibodies between patients with systemic autoimmune diseases and healthy individuals. The anti-vimentin antibodies levels also did not correlate with the AECA positivity.
Introduction
Autoantibodies produced during autoimmune diseases target a variety of antigen epitopes, and many of these are antiendothelial cell antibodies (AECAs). AECAs bind with low affinity to different endothelial structures, mainly via the F(ab) 2 portion of the immunoglobulin. AECAs have been detected in many vasculopathies, including systemic lupus erythematosus, systemic sclerosis, antiphospholipid syndrome, Sjögren's syndrome, and rheumatoid arthritis complicated by vasculitis; however, they can be present in many individuals, even healthy ones. In this case, they probably are so-called natural autoantibodies [1] .
In the current studies, we characterized the antigenic specificity of AECA toward vimentin. An analysis of AECAs from patients with systemic lupus erythematosus by Yazici et al. revealed that vimentin is a major target of AECAs [2] . In addition, Rose et al. [3] [4] [5] identified vimentin as the major endothelial antigen recognized by the sera of patients with transplant-associated coronary artery disease. Furthermore, vimentin is a target for autoimmune reactions not only in bacterial [6, 7] , parasitic [8] , and viral infections [9, 10] but also in rheumatic diseases [11] [12] [13] [14] [15] [16] . Senecal et al. reported that antivimentin antibodies are present along with clinical and serological characteristics typical of both systemic lupus erythematosus and progressive systemic sclerosis [17, 18] , and Uchida et al. found anti-vimentin antibodies in 11 of 68 patients with rheumatoid arthritis and 4 of 19 patients with polymyositis or dermatomyositis [16] . Here, we extended these studies by investigating the relationship between anti-vimentin antibodies and AECAs. 
Detection of serum anti-vimentin autoantibodies by IIF
Anti-vimentin antibodies were detected by IIF in HEp-2 cells. Test samples were incubated with Kallestad T M Hep-2 Cell Line Substrate (Bio-Rad). After washing to remove excess serum from the substrate, fluorescein isothiocyanate-conjugated antiserum was added. The substrate was washed again to remove excess conjugate and coverslipped. Immunofluorescence was viewed with an Olympus BX51 microscope. The typical antivimentin antibody pattern consisted of abundant fine fibers that radiate throughout the cytoplasm and make connections with the nuclear and plasma membranes.
Measurement of serum anti-vimentin antibodies by enzyme-linked immunosorbent assay
The level of anti-vimentin IgG and IgM in the serum samples was measured using the ELISA-VIDITEST (Vidia s.r.o.). Serum was diluted 100-fold and added to wells coated with recombinant human vimentin. For the detection of anti-vimentin IgM, the rheuma toid factor, if present, was removed from the serum speciment by RF sorbent (BIODE-SIGN), to prevent interference with the assay. After incubation and washing, the wells were incubated with peroxidase-conjugated antihuman IgG and IgM antibodies. After further washing of the wells, freshly prepared tetramethylbenzidine was added to each well. Reactions were stopped by adding H 2 SO 4 . Optical densities were measured at 450/630 nm with a Dynex MRXII Revelation double-beam spectrophotometer. The assay was calibrated using a standard solution of the patient's serum. Data are expressed as the mean values of the optical density (OD).
Statistics
Statistical analyses were performed using VassarStats on-line statistical software (http://faculty.vassar.edu/lowry/VassarStats.html). Data are presented as means ± standard deviations unless otherwise indicated. The statistical differences between the means for independent groups were assessed using the non-parametric Mann-Whitney U -test. A P value less than 0.05 was considered to indicate a statistically significant difference.
Results

Correlation between anti-vimentin and AECAs in the patient groups
As show in Table 1 , in the inflammation sample group, 12 out of 50 (24%) sera were AECA-positive, and the mean ODs for IgM and IgG anti-vimentin antibodies in AECApositive samples (0.69 ± 0.21 and 0.26 ± 0.14, respectively) were not significantly different than those of AECA-negative samples (0.57 ± 0.18 and 0.21 ± 0.11, respectively). Similarly, in the autoimmunity group, 16 out of 42 sera (38.1%) were AECA-positive, and the mean ODs of IgM and IgG anti-vimentin antibodies in AECA-positive samples (0.41 ± 0.22 and 0.12 ± 0.08, respectively) were not significantly different than those of AECAnegative samples (0.47 ± 0.18 and 0.14 ± 0.10, respectively). Finally, in the control sample group, 10 out of 58 sera (17.2%) were AECA-positive, and the mean ODs of IgM and IgG anti-vimentin antibodies in AECA-positive samples (0.25 ± 0.15 and 0.10 ± 0.05, respectively) were not significantly different than those in the ;ECA-negative samples (0.28 ± 0.11 and 0.12 ± 0.07, respectively). In summary, there was no significant difference in anti-vimentin antibody levels between AECA-positive and AECA-negative samples in any of the groups. 
Differences in ODs for anti-vimentin antibodies in the three groups of patients irrespective of the AECA findings
Serum anti-vimentin antibodies levels were significantly higher in patients with nonautoimmune inflammatory diseases than in those with systemic autoimmune diseases or healthy controls. Surprisingly, there were no differences between anti-vimentin antibodies levels between groups of systemic autoimmune diseases and healthy blood donors ( Fig. 2a and b) .
Discussion
The present study shows that serum anti-vimentin antibody levels do not correlate with the presence of AECA in any of investigated group of samples. This was an unexpected result because the properties of vimentin could make it a good antibody target. Vimentin is a cytoskeletal protein. Cytoskeletal proteins provide structure to the cell, resisting mechanical stress and preventing cellular deformation, although they also participate in dynamic changes in cell shape and motility [20] . Cytoskeletal proteins can be classified into three groups: microtubules, microfilaments, and intermediate filaments contacts in endothelial cells (EC), which stabilizes the interaction between the cell and the extracellular matrix [22] . Vimentin is the most ubiquitous IF expressed in a wide variety of mesenchymal cell types, but during the differentiation of ECs, vimentin is replaced by other cytoskeletal proteins (e.g., desmin). ECs contain an extensive interconnecting cytoplasmic network of vimentin. Several physiological roles have been proposed for vimentin, including the determination and maintenance of cell shape, transmission of mechanical stress, targeting of molecules between the nucleus and cytoplasm, and the regulation of nuclear position and morphology. Although the vimentin-type IF network has traditionally been regarded as static, recent studies have revealed that it is dynamic in ECs [23] . AECAs comprise a very heterogeneous group of autoantibodies against poorly characterized endothelial antigens, and they have been detected in many vasculopathies. AECAs may affect the function of ECs, although probably only after cellular damage or activation. One theory is that AECAs are only an epiphenomenon of vessel integrity injury [24, 25] . Other hypotheses point to a correlation between AECA plasma levels and the activity of different vessel diseases, suggesting that AECAs play a role in the pathophysiology of the associated diseases, especially by inducing endothelial cell activation or apoptosis [26] . Currently, HUVECs are most widely used primary endothelial cell model, including for the detection of AECAs (e.g., by IIF). A major step in understanding the importance of AECAs has been the recent identification of at least 53 possible antigenic targets in HUVEC cells [27] . The identity of many of these are unknown, but they include proteins implicated in cellular motility and plasticity, the regulation of apoptosis, coagulation, antigen presentation, and enzymes, as well as cytoskeletal proteins such as vimentin.
In the current study, we investigated the level of anti-vimentin antibodies in patients with systemic autoimmune diseases (n=42), healthy blood donors (n=58), and patients with acute inflammatory conditions (n=50). ;e found that the anti-vimentin antibodies did not correlate with the presence of AECAs in any of these groups. Therefore, antivimentin antibodies cannot serve as a marker of AECA-positive vasculopathy. Nevertheless, the possibility that anti-vimentin antibodies are absorbed at sites of vascular injury must be explored, perhaps by another method for examining possible immune responses to vimentin, such as B-cell ELISPOT assays. Although we found that high anti-vimentin antibodies titers characterize a subgroup of patients with acute inflammatory diseases, antibodies against vimentin were more closely associated with non-autoimmune inflammation than systemic autoimmune disorders.
In summary, this initial study did not show that vimentin is an important target antigen in these patients, but additional experiments are necessary to explore this further. Secreted vimentin acts as an immunomodulator, and its secretion is stimulated by tumor necrosis factor-α and blocked by interleukin-10, which are pro-and anti-inflammatory cytokines. This extracellular vimentin is involved in the generation of oxidative metabolites and the killing of microbes. Anti-vimentin antibodies might be indicators of a possible secondary immune response during acute infection, and natural anti-vimentin antibodies that inhibit the immunomodulatory function of vimentin may act as important regulatory agents during acute inflammation.
